Myricetin induces apoptosis by inhibiting P21 activated kinase 1 (PAK1) signaling cascade in hepatocellular carcinoma

Molecular and Cellular Biochemistry

Volumn 407, Issue 1-2, 2015, Pages 223-237

  Iyer, Soumya C ^a   Gopal, Ashidha ^a   Halagowder, Devaraj ^a  

^a UNIVERSITY OF MADRAS   (India)

Author keywords

Erk1 2; Myricetin; PAK1; Catenin

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 MORPHOLINO 8 PHENYLCHROMONE; MYRICETIN; P21 ACTIVATED KINASE 1 INHIBITOR; PROTEIN BAX; PROTEIN BCL 2; PROTEIN SERINE THREONINE KINASE INHIBITOR; SURVIVIN; UNCLASSIFIED DRUG; ANALGESIC AGENT; FLAVONOID; P21 ACTIVATED KINASE; PAK1 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BODY WEIGHT; CANCER PREVENTION; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION; LIVER CELL CARCINOMA; MALE; NONHUMAN; PROTEIN EXPRESSION; RAT; SIGNAL TRANSDUCTION; UPREGULATION; ANIMAL; CARCINOMA, HEPATOCELLULAR; CELL PROLIFERATION; DRUG EFFECTS; DRUG SCREENING; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; HEPG2 CELL LINE; HUMAN; LIVER NEOPLASMS; METABOLISM; PATHOLOGY;

ANALGESICS; ANIMALS; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CELL PROLIFERATION; FLAVONOIDS; GENE EXPRESSION REGULATION, NEOPLASTIC; HEP G2 CELLS; HUMANS; LIVER NEOPLASMS; MALE; P21-ACTIVATED KINASES; RATS; SIGNAL TRANSDUCTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84939268353     PISSN: 03008177     EISSN: 15734919     Source Type: Journal    
DOI: 10.1007/s11010-015-2471-6     Document Type: Article

References (43)

1. Farazi PA, DePinho RA (2006) Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer 6:674–687
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ (2008) Cancer statistics. CA Cancer J Clin 58:71–96
3. Anzola M (2004) Hepatocellular carcinoma: role of hepatitis B and hepatitis C viruses proteins in hepatocarcinogenesis. J Viral Hepat 11:383–393
4. Fattovich G, Stroffolini T, Zagni I, Donato F (2004) Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 127:S35–S50
5. Bosch FX, Ribes J, Cleries R, Diaz M (2005) Epidemiology of hepatocellular carcinoma. Clin Liver Dis 9:191–211
6. Buchmann A, Bauer-Hoffmann R, Mahr J, Drinkwater NR, Luz A, Schwarz M (1991) Mutational activation of c-Ha-ras gene in liver tumors of different rodent strains: correlation with susceptibility to hepatocarcinogenesis. Proc Natl Acad Sci USA 88:333–338
7. Downward J (2003) Targeting RAS signaling pathways in cancer therapy. Nat Rev Cancer 3:11–22
8. Bagheri-Yarmand R, Vadlamudi RK, Wang RA, Mendelsohn J, Kumar R (2000) Vascular endothelial growth factor up-regulation via p21-activated kinase-1 signaling regulates heregulin- h1-mediated angiogenesis. J Biol Chem 275:39451–39457
9. Carter JH, Douglass LE, Deddens JA, Colligan BM, Bhatt TR, Pemberton JO, Konicek S, Hom J, Marshall M, Graff JR (2004) Pak-1 expression increases with progression of colorectal carcinomas to metastasis. Clin Cancer Res 10:3448–3456
10. Kumar R, Gururaj AE, Barnes CJ (2006) p21-activated kinases in cancer. Nat Rev Can 6:459–471
11. Bokoch GM (2003) Biology of the p21-activated kinases. Annu Rev Biochem 72:743–781
12. Molli PR, Li DQ, Murray BW, Rayala SK, Kumar R (2009) PAK signaling in oncogenesis. Oncogene 28:2545–2555
13. Higuchi M, Onishi K, Kikuchii C, Gotoh Y (2008) Scaffolding function of PAK in the PDK1–Akt pathway. Nat Cell Biol 10:1356–1364
14. Mao K, Kobayashi S, Jaffer ZM, Huang Y, Volden P, Chernoff J, Liang Q (2008) Regulation of Akt/PKB activity by P21-activated kinase in cardiomyocytes. J Mol Cell Cardiol 44:429–434
15. Ding Q, Xia W, Liu JC, Yang JY, Lee DF, Xia J, Bartholomeusz G, Li Y, Pan Y, Li Z, Barquo RC, Kin J, Lai CC, Tsai FJ, Tsai CH, Hung MC (2005) Erk associates with and primes GSK-3beta for its inactivation resulting in upregulation of beta-catenin. Mol Cell 19:159–170
16. De Luca A, Maiello MR, D’Alessio A, Pergameno M, Normanno N (2012) The RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways: role in cancer pathogenesis and implications for therapeutic approaches. Expert Opin Ther Targets 16:S17–S27
17. Gopal U, Venkatraman J, Devaraj N, Devaraj H (2011) Nuclear translocation of b-catenin correlates with CD44 upregulation in Helicobacter pylori-infected gastric carcinoma. Mol Cell Biochem 357:283–293
18. Gonzalez FJ (2006) Role of β-catenin in the adult liver. Hepatology 43:650–653
19. Lau WY, Lai EC (2008) Hepatocellular carcinoma: current management and recent advances. Hepato Pancreat Dis Int 7:237–257
20. Chahar MK, Sharma N, Dobhal MP, Joshi YC (2011) Flavonoids: a versatile source of anticancer drugs. Pharmacogn Rev 5:1–12
21. Ong KC, Khoo HE (1997) Biological effects of myricetin. Gen Pharmacol 29:121–126
22. Shih YW, Wu PF, Lee YC, Shi MD, Chiang TA (2009) Myricetin suppresses invasion and migration of human lung adenocarcinoma A549 cells: possible mediation by blocking the ERK signaling pathway. J Agric Food Chem 57:3490–3499
23. Cheng L, Sung CL, Jin K, Jun SC (2011) Effects of myricetin, an anticancer compound, on the bioavailability and pharmacokinetics of tamoxifen and its main metabolite, 4-hydroxytamoxifen, in rats. Eur J Drug Metab Pharmacokinet 36:175–182
24. Hai W, Kim C, Song S, Kang C (2001) Study on mechanism of multistep hepatotumorigenesis in rat: development of hepatotumorigenesis. J Vet Sci 2:53–58
25. Khan SM, Devaraj H, Devaraj SN (2011) Chrysin abrogates early hepatocarcinogenesis and induces apoptosis in N-nitrosodiethylamine induced preneoplastic nodules in rats. Toxicol Appl Pharmacol 251:85–94
26. Khan SM, Devaraj H, Devaraj SN (2011) Methylated chrysin, a dimethoxy flavone, partially suppresses the development of liver preneoplastic lesions induced by N-Nitrosodiethylamine in rats. Food Chem Toxicol 49:173–178
27. King J (1965) The dehydrogenases or oxidoreductase-lactate dehydrogenase. In: Van D (ed) Practical clinical enzymology. Nostrand Company Ltd., London, pp 83–93
28. King J (1965) The hydrolases-acid and alkaline phosphatases. In: Van D (ed) Practical clinical enzymology. Nostrand Company Ltd., London, pp 191–208
29. King J (1965) The transferases—alanine and aspartate transaminases. In: Van D (ed) Practical clinical enzymology. Nostrand Company Ltd., London, pp 121–128
30. Rosali SB, Rau D (1972) Serum gamma-glutamyl transpeptidase activity in alcoholism. Clin Chim Acta 39:41–47
31. Bergmeyer HU, Bernt E (1974) Aminotransferases and related enzymes. In: Bergmeyer HU (ed) Methods of enzymatic analysis, 2nd edn. Academic Press, New York, pp 735–763
32. Sell S, Beckar FF (1978) Alpha feto protein. Natl Cancer Inst 60:19–26
33. −ΔΔCT method. Methods 25:402–408
34. Sivaramakrishnan V, Shilpa PNM, Kumar VRP, Devaraj SN (2008) Attenuation of N- nitrosodiethylamine-induced hepatocellular carcinogenesis by a novel flavonol—Morin. Chem Biol Interact 171:79–88
35. Sun F, Zheng XY, Ye J, Wu TT, Wang J, Chen W (2012) Potential anticancer activity of myricetin in human T24 bladder cancer cells both in vitro and in vivo. Nutr Cancer 64:599–606
36. Zhang S, Wang L, Liu H, Zhao G, Ming L (2014) Enhancement of recombinant myricetin on the radiosensitivity of lung cancer A549 and H1299 cells. Diagn Pathol 9:68
37. Shields JM, Pruitt K, McFall A, Shaub A, Der CJ (2000) Understanding Ras: ‘it ain’t over ‘til it’s over’. Trends Cell Biol 10:147–154
38. Feig LA, Buchsbaum RJ (2002) Cell signaling: life or death decision of ras proteins. Curr Biol 12:R259–R261
39. Huynh N, Kevin HL, Baldwin GS, Hong H (2010) P21-activated kinase 1 stimulates colon cancer cell growth and migration/invasion via ERK- and AKT-dependent pathways. Biochim Biophys Acta 1803:1106–1113
40. Balmanno K, Chell SD, Gillings AS, Hayat S, Cook SJ (2009) Intrinsic resistance to the MEK1/2 inhibitorAZD6244 (ARRY-142886) is associated with weak ERK1/2 signalling and/or strong PI3K signalling in colorectal cancer cell lines. Int J Cancer 125:2332–2341
41. Wee S, Jagani Z, Xiang KX, Loo A, Dorsch M, Yao YM, Sellers WR, Lengauer C, Stegmeier F (2009) PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers. Cancer Res 69:4286–4293
42. Almeida M, Han L, Bellido T, Manolagas SC, Kousteni S (2005) Wnt proteins prevent apoptosis of both uncommitted osteoblast progenitors and differentiated osteoblasts by beta-catenin-dependent and -independent signaling cascades involving Src/ERK and phosphatidylinositol 3-kinase/AKT. J Biol Chem 280:41342–41351
43. Mishra R (2010) Glycogen synthase kinase 3 beta: can it be a target for oral cancer. Mol Cancer 9:144